-
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
in PRESS RELEASE 2022 onFerring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
00 -
Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic
in PRESS RELEASE 2022 onFerring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A…
-
Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)
in PRESS RELEASE 2022 on…
-
Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
in PRESS RELEASE 2022 onPivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in…
-
Ferring Pharmaceuticals and Blackstone Life Sciences restructure novel gene therapy collaboration
in PRESS RELEASE 2022 on…
-
-
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
in PRESS RELEASE 2022 on…
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
in PRESS RELEASE 2022 onFerring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based…
-
Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally
in PRESS RELEASE 2022 onFerring announces ground-breaking and inclusive family building benefits package for all its…
-
Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray
in PRESS RELEASE 2022 on
PRESS RELEASE 2022
PRESS RELEASE 2022